Biovica International AB (publ) Stock Nasdaq Stockholm
Equities
SE0008613731
Biotechnology & Medical Research
Sales 2024 * | 10M 919K | Sales 2025 * | 116M 10.66M | Capitalization | 135M 12.39M |
---|---|---|---|---|---|
Net income 2024 * | -110M -10.11M | Net income 2025 * | -51M -4.69M | EV / Sales 2024 * | 4.81 x |
Net cash position 2024 * | 86.7M 7.97M | Net cash position 2025 * | 43.01M 3.95M | EV / Sales 2025 * | 0.79 x |
P/E ratio 2024 * |
-0.12
x | P/E ratio 2025 * |
-0.54
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.54% |
Latest transcript on Biovica International AB (publ)
Managers | Title | Age | Since |
---|---|---|---|
Anders Rylander
CEO | Chief Executive Officer | 54 | 09-12-31 |
Anders Morén
DFI | Director of Finance/CFO | 59 | 22-12-31 |
Hanna Ritzen
CTO | Chief Tech/Sci/R&D Officer | 45 | 21-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 64 | 19-03-19 | |
Annika Berg
BRD | Director/Board Member | 61 | 19-12-31 |
Maria Holmlund
BRD | Director/Board Member | 68 | 15-12-31 |
1st Jan change | Capi. | |
---|---|---|
-20.53% | 11.48B | |
+41.94% | 3.27B | |
-36.56% | 2.2B | |
-18.92% | 2.05B | |
-29.19% | 1.49B | |
+15.73% | 1.01B | |
-4.37% | 743M | |
-37.00% | 413M | |
-46.73% | 377M |